We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Waters and Tecan Sign Agreement for Clinical Assay Platform

By LabMedica International staff writers
Posted on 25 Jan 2012
Waters Corporation (Milford, MA, USA) and Tecan Group (Männedorf, Switzerland) entered into an agreement to combine Tecan’s Freedom EVO liquid handling platform with Waters Acquity TQD liquid chromatograph/mass spectrometer (LC/MS/MS) to automate sample preparation. More...
This will enable better, more efficient, and higher throughput clinical LC/MS assays.

Waters will combine the technologies from both companies into a single, fully supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve profitability, and reduce overall assay costs.

The firms announced the agreement at the annual meeting of the Association for Mass Spectrometry Applications to the Clinical Lab (MSACL) held on January 14-18, 2012, in San Diego (CA, USA).

"The multistep process of preparing samples for LC/MS/MS analyses remains a significant bottleneck and an opportunity for improvement in many laboratories. If there is one thing laboratory managers consistently ask for, it’s better, more automated sample preparation and analysis,” said Pat Martell, clinical marketing director, Waters Division. “Combining sample preparation and analysis in a single unified platform facilitates the entire assay process and streamlines analyses significantly. By lowering assay costs and bringing a greater consistency to test results, laboratories can offer clients a higher level of service and responsiveness."

Tecan is a global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production, and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories.

Waters innovations and laboratory solutions deliver better accuracy and precision for assays. The company is committed to helping laboratories deliver quality results with new levels of sample throughput, shortened turnaround times, and increases in sensitivity, specificity, and flexibility.

Related Links:
Waters Corporation
Tecan Group
The Association for Mass Spectrometry Applications to the Clinical Lab


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.